DEALS: Ligand sells cancer drugs for $205M
Ligand sells cancer drugs for $205M
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Ligand Pharmaceuticals |
Eisai |
$205M sale |
Ligand Pharmaceuticals has sold a line of cancer drugs to Eisai. |
|
Daiichi Sankyo |
Kearney Venture Partners |
$60M investment |
The deal allows Daiichi to strike collaborations with the biotech companies who gain funds from the venture group. |
|
Sankyo |
Ajinomoto |
Licensing deal |
Sankyo has gained the exclusive global rights to develop, manufacture and market the new diabetes drug AJD101. |
|
Omeros |
Nura |
Cash/stock buyout |
Omeros' acquisition will add Nura's work in schizophrenia and Parkinson's disease. The three investors in Nura are making an unspecified but "large" investment in Omeros. |
|
Genzyme |
AnorMed |
Hostile takeover |
Genzyme says it will pursue a hostile takeover of AnorMed with a tender offer of $8.55 per share, a 70 percent premium on the Canadian biotech's trading price. |
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
